1. Introduction {#sec1-molecules-16-06023}
===============

Numerous experimental studies indicate that natural and synthetic coumarins (2*H*-1-benzopyran-2-ones) and their derivatives are endowed with excellent chemical reactivity and different bioactivity. Thus, the natural coumarins play an important role in plant biochemistry and physiology. They act as antioxydants, enzyme inhibitors and precursors of toxic substances. They are also involved in the actions of plant growth hormones and growth regulators, the control over the respiration and photosynthesis, as well as in the defense against various infections \[[@B1-molecules-16-06023]\]. Although most of the existing natural coumarins have been isolated from higher plants, some of them have been discovered in microorganisms, e.g., aminocoumarin antibiotics: Novobiocin, coumermycin A~1~ and chlorobiocin (produced by the actinomycete *Streptomyces niveus*) \[[@B2-molecules-16-06023]\].

Synthetic coumarin derivatives have been obtained by chemical modification of the coumarin ring. As a substitution can conceptually occur at any of the six available sites of the basic molecule, these compounds are widely variable in structure and activity. The biological activities of coumarin derivatives, in particular their therapeutic application as anticoagulant and antibacterial agents \[[@B3-molecules-16-06023]\], has stimulated further interest for the synthesis of this class of compounds. A variety of synthesized coumarin derivatives have been experimentally shown to exert pharmacological activities including inhibition of platelet aggregation, cytochrome P450, and steroid 5-α-reductase.

They have also been shown to exert efficient anti-proliferative, antifungal, anti-psoriasis, anti-inflammatory, as well as antiviral activities \[[@B4-molecules-16-06023],[@B5-molecules-16-06023],[@B6-molecules-16-06023],[@B7-molecules-16-06023],[@B8-molecules-16-06023]\]. The interest in coumarins has recently increased significantly because it was found that they inhibit HIV (human immunodeficiency virus), by affecting integrase and reverse transcriptase, which play a critical role in the replicative cycle of HIV \[[@B9-molecules-16-06023],[@B10-molecules-16-06023],[@B11-molecules-16-06023]\]. The present study is focused on the antiviral activity evaluation of the benzylidene-bis-(4-hydroxycoumarin) derivatives **1**--**15** and 3-\[6-oxo-(1*H*)-benzopyrano\[4,3-b\]benzopyran-7-yl\]-4-hydroxycoumarin derivatives **16**--**20** ([Figure 1](#molecules-16-06023-f001){ref-type="fig"}).

2. Results and Discussion {#sec2-molecules-16-06023}
=========================

2.1. Chemistry {#sec2dot1-molecules-16-06023}
--------------

The benzylidene-bis-(4-hydroxycoumarin) derivatives **1**--**15** and fused benzopyranocoumarin derivatives **16**--**20** were prepared by a sequence of reactions displayed in the [Scheme 1](#molecules-16-06023-sch001){ref-type="scheme"}. In the first step of the synthesis the aldol condensation of 4-hydroxycoumarin (**4-HC**) with an appropriately substituted aldehyde linker followed by dehydration of aldol product (**AL**) gave a chromone (**CR**). Subsequent *in situ* reaction of the chromon with 4-hydroxycoumarin already present in excess in the reaction mixture gave dimeric coumarin derivatives **1**--**15** bearing an aryl substituent in the central methylene linker. In contrast, the chromone derivatives containing an *ortho*-substituted phenyl moiety (R^1^ = Cl, F, OH, OCH~3~) gave under spontaneous cyclization the fused benzopyranocoumarin derivatives **16**--**20**. The compounds **1** \[[@B11-molecules-16-06023],[@B14-molecules-16-06023],[@B16-molecules-16-06023]\], **2** \[[@B11-molecules-16-06023],[@B13-molecules-16-06023],[@B14-molecules-16-06023]\], **4** \[[@B14-molecules-16-06023]\], **5** \[[@B14-molecules-16-06023]\], **6** \[[@B13-molecules-16-06023]\], **8** \[[@B14-molecules-16-06023]\], **9** \[[@B11-molecules-16-06023],[@B14-molecules-16-06023]\], **10** \[[@B14-molecules-16-06023]\], **11** \[[@B14-molecules-16-06023]\], **12** \[[@B11-molecules-16-06023],[@B14-molecules-16-06023]\] and **16** \[[@B17-molecules-16-06023],[@B18-molecules-16-06023]\] that have been described previously were also synthesized for their antiviral activity evaluations.

2.2. NMR Assignment and Conformational Study {#sec2dot2-molecules-16-06023}
--------------------------------------------

The chemical identities and structures of **1**--**20** were confirmed by homo- and heteronuclear NMR measurements. ^1^H-, ^13^C- and ^19^F-NMR chemical shifts are reported in the Experimental section. Proton-decoupled ^13^C-NMR spectra showed C--F coupling constants that enabled straightforward identification of fluorinated carbon atoms and their neighbors. In the ^1^H spectrum of **1**, **2**, **4** and **10**, which were dissolved in non-polar solvents, well resolved hydroxyl protons were observed in the range from δ 11.3 to 11.5 ppm (see Experimental section for details). The strongly deshielded signals suggest that OH protons are most probably involved in hydrogen bond formation. In addition, two set of ^1^H-NMR signals were observed for H5 and H5" protons which indicates a slight difference in magnetic environment for otherwise symmetrical moieties. Furthermore, hydroxyl protons, which were observed between δ 11.8 and 12.3 ppm for benzopyranocoumarin derivatives **16**, **18** and **20**, are most likely involved in hydrogen bonds.

Hydrogen bonds described above partially determined conformational preferences of the studied compounds. Conformational properties of **5**, **14** and **20** were assessed with the use of 1D NOE difference experiments. Key NOE enhancements are shown in [Figure 2](#molecules-16-06023-f002){ref-type="fig"}. The saturation of H\* in **5** resulted in weak NOE at H6′ (1.5%) and 2′-OCH~3~ (0.8%, [Figure 2](#molecules-16-06023-f002){ref-type="fig"}a).

Likewise, the saturation of H\* in **14** gave moderate NOE at H6′ (3.7%) and weak NOE at 2′-OCH~3~ (0.8%). These observations suggested nonrestricted rotation along C\*--C1′ bonds in **5** and **14**. No NOEs indicative of relative orientations of individual heterocyclic moieties were observed for **20**. Interestingly, benzopyranocoumarin derivatives **16**, **18** and **20** showed two sets of signals in the ^1^H spectrum for coumarin protons. One set of ^1^H signals (H5-H8 protons) exhibited broader line-widths with respect to multiplets attributed to H5"-H8" protons. This phenomenon was studied in more detail for **20** by variable temperature experiments in the range from 298 to 358 K. As an example, broad multiplet at δ 8.00 ppm corresponding to H5 becomes sharper at higher temperatures ([Figure 3](#molecules-16-06023-f003){ref-type="fig"}). This suggests that rotation along C\*--C3 bond is restricted at lower temperatures, most likely due to formation of hydrogen bond between the C4-OH and C2" carbonyl group (for enumeration of atoms *c.f.* [Figure 2](#molecules-16-06023-f002){ref-type="fig"}).

2.3. X-Ray Crystal Structure Study {#sec2dot3-molecules-16-06023}
----------------------------------

In **7** ([Figure 4](#molecules-16-06023-f004){ref-type="fig"}a) and **9** ([Figure 4](#molecules-16-06023-f004){ref-type="fig"}b), two 4-hydroxycoumarin moieties are linked through a methylene bridge on which one hydrogen atom has been replaced with a phenyl ring bearing *p*-trifluoromethyl and *o*-nitro groups, respectively. In general, the geometry of the molecules agrees with closely related structures \[[@B19-molecules-16-06023],[@B20-molecules-16-06023],[@B21-molecules-16-06023]\].

The exocyclic bond angles around C3 atom in **7** and **9** differ by even 11.7^o^ and 11.6^o^, respectively. The corresponding angles about C3′ atom of the coumarin ring differ by only 5.6^o^ in **7** and 4.0^o^ in **9**. This asymmetry, which is also found in similar structures, may be a consequence of steric crowding within the molecules. Because of the same reason all principal bond angles about C11 are widened over normal tetrahedral values, ranging from 112.5(2) to 115.4(2)° in **7** and 111.75(12) to 115.63(12)° in **9**. The coumarin rings are slightly distorted from planarity, with two planes inclined at 57.83(11)° and 59.55(5)° to each other in **7** and **9**, respectively.

The 4-hydroxycoumarin moieties are intramolecularly hydrogen bonded between hydroxyl and carbonyl oxygen atoms in both structures (see [Figure 4](#molecules-16-06023-f004){ref-type="fig"}a and [Figure 4](#molecules-16-06023-f004){ref-type="fig"}b and [Table S1 in ESI](#app1-molecules-16-06023){ref-type="app"}), thus forming two eight-membered rings. Thus, compounds **7** and **9** adopt a conformation in which two 4-hydroxycoumarin moieties are anti-disposed. Benzylidene bis (4-hydroxycoumarin) derivatives **7** and **9** form supramolecular self-assemblies by C−H···O hydrogen bonds ([Figures S1 and S2, see ESI](#app1-molecules-16-06023){ref-type="app"}) in which infinite chains are extended by one F···F interaction between trifluoromethyl fluorine atoms in **7** \[F2···F2*^i^* = 2.934(5) Å; (*i*): −x, −y, −z\] and one π···π interaction in **9**. The distance between the ring centroids of coplanar C5′--C10′ rings \[*α* = 0^o^\] in **9** is 3.6832(12) Å, the planes are separated by 3.5132(8) Å and centroids offset is *ca*. 1.11 Å.

Cyclized compound **16** ([Figure 5](#molecules-16-06023-f005){ref-type="fig"}a) crystallized with two independent molecules, two ethanol molecules and one water molecule in the asymmetric unit in monoclinic space group *P* 2~1~/*c*. The bond lengths in two independent molecules of **16**, denoted as A and B, are within 2*σ* values, and agree very well with the corresponding ones in **18** ([Figure 5](#molecules-16-06023-f005){ref-type="fig"}b).

The main structural difference between these two structures is in orientation of the coumarin rings. The coumarin ring in **18** is flipped by approximately 180^o^ compared to the situation in **16**, and such ring orientation enables O−H···O intramolecular hydrogen bond formation ([Table S1, see ESI](#app1-molecules-16-06023){ref-type="app"}). Two independent molecules of **16**, two ethanol molecules and water molecule are linked by six O−H···O and four C−H···O hydrogen bonds into three-dimensional network ([Figure S3, see ESI](#app1-molecules-16-06023){ref-type="app"}). Two C−H···π interactions participate also in supramolecular aggregation. On the contrary, only one hydrogen bond of C−H···O type links the molecules of **18**, thus forming discrete centrosymmetric dimers *via* 20-membered rings ([Figure S4, see ESI](#app1-molecules-16-06023){ref-type="app"}).

2.4. Biological Activity Results {#sec2dot4-molecules-16-06023}
--------------------------------

*Antiviral activity*.-Compounds **1**--**20** were evaluated for their inhibitory activities against herpes simplex virus type 1 and 2 \[HSV-1 (KOS), HSV-2 (G)\], vaccinia virus, vesicular stomatitis virus and herpes simplex virus-1 TK^−^ KOS (ACV^r^) in HEL cell cultures. Their activities were compared with those of brivudin \[(*E*)-5-(2-bromovinyl)-2'-deoxyuridine\], cidofovir \[(*S*)-1-\[3-hydroxy-2-(phosphonyl-methoxy)propyl\]cytosine\], acyclovir \[9-(3-hydroxyethoxymethyl)guanine\] and gancyclovir \[9-\[(1,3-dihydroxy-2-propoxy)methyl\]guanine\] ([Table 1](#molecules-16-06023-t001){ref-type="table"}, only data for the selected number of compounds **1**, **4**--**6**, **8**, **9** and **20** are shown).

Of all evaluated compounds only the 3-bromobenzylidene derivative **3** of bis(4-hydroxycoumarin) showed potentially interesting inhibitory activity against HSV-1 (KOS), HSV-2 (G), vaccinia virus and HSV-1 TK^−^ KOS (ACV^r^) in the range of 9--12 μM at a minimum cytotoxic concentration (MCC) greater than 20 μM, whereas compound **19** showed only slight activity against HSV-1 (KOS), HSV-2 (G) and HSV-1 TK^−^ KOS (EC~50~ = 45--50 μM) in human embryonic lung HEL cell cultures and no cytotostatic activity at 100 µM ([Table 1](#molecules-16-06023-t001){ref-type="table"}, data taken together from two independent experiments). Evaluation of compounds **1**--**20** on Feline corona virus (FIPV) and Feline herpes virus activity and cytotoxicity in Crandell-Rees feline kidney (CRFK) cell cultures showed that the benzylidene-bis-(4-hydroxycoumarin) derivatives **1**, **4**--**6**, **8** and **9**, and the benzopyranocoumarin derivative **20** exerted *anti*-FIPV activity (EC~50~ = 7.2--10 μM) in CRFK cell cultures. Such activity is within the same magnitude as that of the plant lectin *Urtica dioica agglutinin* (UDA) \[[@B10-molecules-16-06023]\] (EC~50~ = 6 μM) but less active than *Hyppeastrum hybride agglutinin* (HHA) \[[@B12-molecules-16-06023]\] (EC~50~ = 0.38 μM). However it should be noted that the novel compounds showed cytostatic activities at concentrations that are only 4-5-fold higher than the antiviral active concentrations and therefore, it can be questioned whether the antiviral effect observed represents a direct antiviral effect or elicited indirectly by the cytotoxic activity of the test compounds. Similarly, the compounds **4**--**6**, **8** and **20** exhibited *anti*-Feline Herpes Virus activity (EC~50~ = 5--8.1 μM) the MCC were only 4-7-fold higher than the EC~50~ values ([Table 2](#molecules-16-06023-t002){ref-type="table"}, only selected data for compounds **1**, **4**--**6**, **7**, **8** and **20** are shown).

Compounds **1**--**20** were also evaluated for their cytotoxicity and antiviral activities against Coxsackie virus B4 and respiratory syncytial virus (RSV) in HEL cell cultures; parainfluenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4 and Punta Toro virus in Vero cell cultures; and influenza virus subtypes A H1N1 and H3N2, and influenza virus B. No specific antiviral effects (*i.e*., antivirally effective concentration \>5-fold lower than the minimal cytotoxic concentration) were noted for any of the evaluated compounds.

3. Experimental {#sec3-molecules-16-06023}
===============

3.1. General Methods {#sec3dot1-molecules-16-06023}
--------------------

Melting points (uncorrected) were determined with Büchi melting point B-545. Precoated Merck silica gel 60F-254 plates were used for thin-layer chromatography (TLC) and the spots were detected under UV light (254 nm). Solvent system used for TLC was chloroform:methanol = 9:1. Mass spectra were recorded with an Autospec: ESI/Q-TOF Premier instrument. ^1^H-NMR spectra were recorded at 600 MHz, in deuterated DMSO-d6, on Bruker (UXNMR/XwinNMR) spectrometer, using tetramethylsilane (TMS) as internal reference. 1D and 2D NMR spectra were recorded at 25 °C on Varian Unity Inova 300 spectrometers. ^1^H and ^13^C chemical shifts were referred to residual signal of CDCl~3~, CD~2~Cl~2~ and DMSO-d~6~ (δ~TMS~ 0.0 ppm). ^19^F chemical shifts were referenced externally with respect to CCl~3~F (δ 0.0 ppm). ^1^H, ^13^C and ^19^F-NMR resonances were assigned on the basis of signal intensities and multiplicities in 1D spectra as well as correlation signals in 2D ^1^H-^1^H COSY, ^1^H-^13^C HSQC and ^1^H-^13^C HMBC NMR spectra. Elemental analyses were performed in the Central Analytic Service, Rudjer Bošković Institute Zagreb, Croatia, using a Perkin Elmer 2400 Elemental Analyser. The infrared spectra were obtained from potassium bromide triturate containing 0.5% of the product on a Perkin-Elmer 1000 FT-IR spectrophotometer. All data were recorded at 25 °C unless specified otherwise.

3.2. Procedures for the Preparation of Compounds {#sec3dot2-molecules-16-06023}
------------------------------------------------

### 3.2.1. The compounds 1--20 were prepared by the following general procedure {#sec3dot2dot1-molecules-16-06023}

4-Hydroxycoumarin (2 mmol) was dissolved in hot ethanol (6 mL), the corresponding aldehyde (1 mmol) was added, and the reaction mixture was refluxed for 24 h. After cooling to room temperature, the solid was filtered off and crystallized to give the product benzylidene-bis-(4-hydroxycoumarin) derivatives **1**--**15** and 3-\[6-oxo-(1*H*)-benzopyrano\[4,3-b\]benzopyran-7-yl\]-4-hydroxycoumarin derivatives **16**--**20** ([Figure 1](#molecules-16-06023-f001){ref-type="fig"}).

### 3.2.2. Compound data {#sec3dot2dot2-molecules-16-06023}

*3,3′-(Benzilidene)-bis-\[4-hydroxycoumarin\]* (**1**) \[[@B11-molecules-16-06023],[@B14-molecules-16-06023],[@B16-molecules-16-06023]\]. Yield 77.5%; mp 233.3 °C; IR (KBr) (ν, cm^−1^): 2901 (CH); 1658 (C=O); 1600, 1584, 1497, 1450 (C=C ar.); 1199 (OH); ^1^H-NMR (CDCl~3~): δ 6.11 (H\*, s, 1H), 7.23 (H2′/H6′, m, 2H), 7.27 (H4′, m, 1H), 7.33 (H3′/H5′, m, 2H), 7.38 (H6/H6\", m, 2H), 7.42 (H8/H8\", m, 2H), 7.63 (H7/H7\", m, 2H), 8.00 (H5/H5\", d, *J* = 7.3, 1H), 8.08 ppm (H5/H5\", d, *J* = 6.8, 1H), 11.41 (OH, b, 2H); ^13^C-NMR (CDCl~3~): δ 36.16 (C\*), 103.90/105.63 (C3/C3\"), 116.63 (C8/C8\"), 116.91 (C10/C10\"), 124.39 (C5/C5\"), 124.88 (C6/C6\"), 126.47 (C2′/C6′), 126.87 (C4′), 128.63 (C3′/C5′), 132.85 (C7/C7\"), 135.17 (C1′), 152.29/152.53 (C9/C9\"), 164.60/165.80 (C4/C4\"), 166.87/169.31 ppm (C2/C2\"); ES-MS *m/z* 413 \[M−H\].

*3,3′-(4-Bromobenzylidene)-bis-\[4-hydroxycoumarin\]* (**2**) \[[@B11-molecules-16-06023],[@B13-molecules-16-06023],[@B14-molecules-16-06023]\]. Yield 74%; mp 267.2 °C; IR (KBr) (ν, cm^−1^): 3276 (OH), 2730 (CH), 1772 (C=O), 1668 (C=C--C=O), 1604, 1564, 1488, 1454 (C=C), 646 (C--Br); ^1^H-NMR (CDCl~3~): δ 6.02 (H\*, s, 1H), 7.10 (H2′/H6′, m, 2H), 7.38 (H6/H6\", m, 2H), 7.41 (H8/H8\", m, 2H), 7.44 (H3′/H5′, m, 2H), 7.64 (H7/H7\", m, 2H), 7.99 (H5/H5\", d, *J* = 7.7, 1H), 8.07 (H5/H5\", d, *J* = 7.3, 1H), 11.32 ppm (OH, s, 1H), 11.54 (OH, s, 1H); ^13^C-NMR (CDCl~3~): δ 35.87 (C\*), 103.62/105.18 (C3/C3\"), 116.33/116.67 (C10/C10\"), 116.69 (C8/C8\"), 120.80 (C4′), 124.41 (C5/C5\"), 125.00 (C6/C6\"), 128.33 (C2′/C6′), 131.70 (C3′/C5′), 133.04 (C7/C7\"), 134.41 (C1′), 152.28/152.53 (C9/C9\"), 164.64/166.03 (C4/C4\"), 166.84/169.21 ppm (C2/C2\"); ES-MS *m/z* 491 \[M−H\]. Elemental analysis. Calc. for C~25~H~15~O~6~Br: C 61.12, H 3.08, Found: C 61.07, H 3.13.

*3,3′-(3-Bromobenzylidene)-bis-\[4-hydroxycoumarin\]* (**3**). Yield 83%; mp 287 °C; IR (KBr) (ν, cm^−1^): 2918 (CH), 1774 (C=O), 1648 (C=C--C=O), 1610, 1568, 1498, 1452 (C=C), 1196 (OH), 970 (C--Br); ^1^H-NMR (DMSO-d~6~): δ 6.31 (H\*, d, *J* = 0.9, 1H), 7.14 (H6′, m, 1H), 7.18 (H5′, m, 1H), 7.26 (H2′, m, 1H), 7.29 (H6/H6\", m, 2H), 7.32 (H4′, m, 1H), 7.33 (H8/H8\", m, 2H), 7.57 (H7/H7\", m, 2H), 7.88 ppm (H5/H5\", dd, *J* = 7.9, 1.7, 2H); ^13^C-NMR (DMSO-d~6~): δ 36.02 (C\*), 103.32 (C3/C3\"), 115.80 (C8/C8\"), 118.75 (C10/C10\"), 121.46 (C3′), 123.41 (C6/C6\"), 124.03 (C5/C5\"), 126.00 (C6′), 128.23 (C4′), 129.26 (C2′), 130.12 (C5′), 131.58 (C7/C7\"), 144.40 (C1′), 152.37 (C9/C9\"), 164.49 (C2/C2\"), 166.51 ppm (C4/C4\"); ES-MS *m/z* 491 \[M−H\]. Elemental analysis. Calc. for C~25~H~15~O~6~Br: C 61.12, H 3.08, Found: C 61.24, H 3.11.

*3,3'-(4-Chlorobenzylidene)-bis-\[4-hydroxycoumarin\]* (**4**) \[[@B14-molecules-16-06023]\]. Yield 82%; mp 256.7 °C; IR (KBr) (ν, cm^−1^): 2858 (CH), 1828 (C=O), 1668 (C=C--C=O), 1604, 1562, 1490, 1454 (C=C), 1182 (OH), 706 (C--Cl); ^1^H-NMR (CDCl~3~): δ 6.04 (H\*, s, 1H), 7.16 (H2′/H6′, m, 2H), 7.29 (H3′/H5′, m, 2H), 7.39 (H6/H6\", m, 2H), 7.41 (H8/H8\", m, 2H), 7.64 (H7/H7\", m, 2H), 8.00 (H5/H5\", d, *J* = 7.7, 1H), 8.07 (H5/H5\", d, *J* = 7.7, 1H), 11.32 (OH, b, 1H), 11.54 ppm (OH, b, 1H); ^13^C-NMR (CDCl~3~): δ 35.80 (C\*), 103.69/105.25 (C3/C3\"), 116.34/116.81 (C10/C10\"), 116.67 (C8/C8\"), 124.42 (C5/C5\"), 124.99 (C6/C6\"), 127.97 (C2′/C6′), 128.77 (C3′/C5′), 132.73 (C4′), 133.04 (C7/C7\"), 133.84 (C1′), 152.28/152.53 (C9/C9\"), 164.65/166.01 (C4/C4\"), 166.85/169.21 ppm (C2/C2\"); ES-MS *m/z* 447 \[M−H\]. Elemental analysis. Calc. for C~25~H~15~O~6~Cl: C 67.19, H 3.38, Found: C 67.16, H 3.49.

*3,3′-(2-Methoxybenzylidene)bis\[4-hydroxycoumarin\]* (**5**) \[[@B14-molecules-16-06023]\]. Yield 82%; mp 254.7 °C; IR (KBr) (ν, cm^−1^): 3030 (C--CH); 2898 (CH); 1670 (C=C--C=O), 1604, 1566, 1498, 1450 (C=C), 1192 (OH), 660 (C--Cl); ^1^H-NMR (DMSO-d~6~): δ 3.57 (OCH~3~, s, 3H), 6.25 (H\*, s, 1H), 6.84 (H5′, m, 1H), 6.89 (H3′, d, *J* = 7.9, 1H), 7.16 (H6′, m, 1H), 7.17 (H4′, m, 1H), 7.32 (H6/H6\", m, 2H), 7.36 (H8/H8\", d, *J* = 8.0, 2H), 7.58 (H7/H7\", m, 2H), 7.90 ppm (H5/H5\", dd, *J* = 7.9, 1.2, 2H); ^13^C-NMR (DMSO-d~6~): δ 32.93 (C\*), 55.51 (OCH~3~), 104.80 (C3/C3\"), 110.94 (C3′), 115.91 (C8/C8\"), 117.54 (C10/C10\"), 119.85 (C5′), 123.60 (C5/C5\"), 123.67 (C6/C6\"), 127.29 (C4′), 128.22 (C6′), 128.29 (C1′), 131.63 (C7/C7\"), 151.98 (C9/C9\"), 157.34 (C2′), 163.63 (C4/C4\"), 163.99 ppm (C2/C2\"); ES-MS *m/z* 447 \[M−H\].

*3,3′-(4-Fluorobenzylidene)-bis-\[4-hydroxycoumarin\]* (**6**) \[[@B13-molecules-16-06023]\]. Yield 86%; mp 214.5 °C; IR (KBr) (ν, cm^−1^): 2858 (CH), 1774 (C=O), 1675 (C=C--C=O), 1608, 1534, 1508, 1454 (C=C), 1188 (OH), 1030 (C--F); ^1^H-NMR (DMSO-d~6~): δ 6.31 (H\*, m, 1H), 7.03 (H3′/H5′, m, 2H), 7.17 (H2′/H6′, m, 2H), 7.31 (H6/H6\", m, 2H), 7.35 (H8/H8\", m, 2H), 7.58 (H7/H7\", m, 2H), 7.89 ppm (H5/H5\", dd, *J* = 7.9, 1.7, 2H); ^13^C-NMR (DMSO-d~6~): δ 35.48 (C\*), 104.01 (C3/C3\"), 114.58 (C3′/C5′, d, *J~CF~* = 20.9), 115.88 (C8/C8\"), 118.23 (C10/C10\"), 123.59 (C6/C6\"), 123.93 (C5/C5\"), 128.52 (C2′/C6′, d, *J~CF~* = 7.7), 131.76 (C7/C7\"), 136.34 (C1′, d, *J~CF~* = 2.8), 152.26 (C9/C9\"), 160.42 (C4′, d, *J~CF~* = 241.2), 164.66 (C2/C2\"), 165.68 ppm (C4/C4\"). ^19^F-NMR (DMSO-d~6~): δ --117.92 ppm (C4′-F, m); ES-MS *m/z* 431 \[M−H\].

*3,3′-(4-Trifluoromethylbenzylidene)-bis-\[4-hydroxycoumarin\]* (**7**). Yield 72%; mp 271.3 °C; IR (KBr) (ν, cm^−1^): 2918 (CH), 1778 (C=O), 1652 (C=C--C=O), 1604, 1568, 1504, 1454 (C=C), 1470 (C--C), 1198 (OH), 1028 (C--F); ^1^H-NMR (DMSO-d~6~): δ 6.34 (H\*, d, *J* = 0.9, 1H), 7.27 (H6/H6\", m, 2H), 7.31 (H8/H8\", m, 2H), 7.34 (H2′/H6′, d, *J* = 8.4, 2H), 7.55 (H7/H7\", m, 2H), 7.55 (H3′/H5′, d, *J* = 8.4, 2H), 7.85 ppm (H5/H5\", dd, *J* = 7.8, 1.5, 2H); ^13^C-NMR (DMSO-d~6~): δ 36.33 (C\*), 103.18 (C3/C3\"), 115.70 (C8/C8\"), 119.07 (C10/C10\"), 123.25 (C6/C6\"), 124.07 (C5/C5\"), 124.58 (CF~3~, q, *J~CF~* = 271.7), 124.77 (C3′/C5′, q, *J~CF~* = 4.2), 125.92 (C4′, q, *J~CF~* = 31.6), 127.44 (C2′/C6′), 131.43 (C7/C7\"), 146.86 (C1′), 152.44 (C9/C9\"), 164.44 (C2/C2\"), 166.95 ppm (C4/C4\"); ^19^F-NMR (DMSO-d~6~): δ --60.03 ppm (CF~3~, s); ES-MS *m/z* 481 \[M−H\]. Elemental analysis. Calc. for C~26~H~15~O~6~F~3~: C 65.01, H 3.15, F 11.86, Found: C 65.11, H 3.25, F 11.97.

*3,3′-(4-Nitrobenzylidene)-bis-\[4-hydroxycoumarin\]* (**8**) \[[@B14-molecules-16-06023]\]. Yield 84%; mp 236.3 °C; IR (KBr) (ν, cm^−1^): 2858 (CH), 1794 (C=O); 1656 (C=C--C=O), 1600, 1562, 1492, 1454 (C=C); 1390, 1518 (NO~2~); 1196 (OH); ^1^H-NMR (DMSO-d~6~): δ 6.38 (H\*, m, 1H), 7.28 (H6/H6\", m, 2H), 7.33 (H8/H8\", m, 2H), 7.40 (H2′/H6′, m, 2H), 7.57 (H7/H7\", m, 2H), 7.86 (H5/H5\", dd, *J* = 7.8, 1.5, 2H), 8.08 ppm (H3′/H5′, m, 2H); ^13^C-NMR (DMSO-d~6~): δ 36.70 (C\*), 103.13 (C3/C3\"), 115.78 (C8/C8\"), 118.83 (C10/C10\"), 123.17 (C3′/C5′), 123.36 (C6/C6\"), 124.07 (C5/C5\"), 128.00 (C2′/C6′), 131.60 (C7/C7\"), 145.46 (C4′), 150.48 (C1′), 152.44 (C9/C9\"), 164.36 (C2/C2\"), 166.79 ppm (C4/C4\"); ES-MS *m/z* 458 \[M−H\].

*3,3'-(2-Nitrobenzylidene)-bis-\[4-hydroxycoumarin\]* (**9**) \[[@B11-molecules-16-06023],[@B14-molecules-16-06023]\]. Yield 73.5%; mp 202 °C; IR (KBr) (ν, cm^−1^): 2874 (CH), 1816 (C=O); 1656 (C=C--C=O), 1604, 1568, 1494, 1452 (C=C), 1524, 1355 (NO~2~), 1199 (OH); ^1^H-NMR (DMSO-d~6~): δ 6.52 (H\*, s, 1H), 7.27 (H6/H6\", m, 2H), 7.31 (H8/H8\", m, 2H), 7.39 (H4′, m, 1H), 7.40 (H6′, m, 1H), 7.53 (H5′, m, 1H), 7.55 (H7/H7\", m, 2H), 7.64 (H3′, m, 1H), 7.83 ppm (H5/H5\", dd, *J* = 7.8, 1.5, 2H); ^13^C-NMR (DMSO-d~6~): δ 34.18 (C\*), 103.07 (C3/C3\"), 115.84 (C8/C8\"), 118.24 (C10/C10\"), 123.37 (C6/C6\"), 123.86 (C5/C5\"), 123.98 (C3′), 126.96 (C4′), 129.80 (C6′), 131.54 (C7/C7\"), 131.84 (C5′), 134.89 (C1′), 149.48 (C2′), 152.35 (C9/C9\"), 163.32 (C2/C2\"), 165.84 ppm (C4/C4\"); ES-MS *m/z* 458 \[M−H\] (Elemental analysis. Calc. for C~25~H~15~O~8~N: C 65.65, H 3.31, N 3.06, Found: C 65.59, H 3.28, N 3.06.

*3,3'-(4-Methoxybenzylidene)-bis-\[4-hydroxycoumarin\]* (**10**) \[[@B14-molecules-16-06023]\]. Yield 80%; mp 248.4 °C; IR (KBr) (ν, cm^−1^): 2902 (CH); 1652 (C=C--C=O), 1604, 1564, 1496, 1454 (C=C), 1360 (CH~3~O), 1194 (OH); ^1^H-NMR (CD~2~Cl~2~): δ 3.79 (OCH~3~, s, 3H), 6.03 (H\*, s, 1H), 6.85 (H3′/H5′, m, 2H), 7.13 (H2′/H6′, m, 2H), 7.43 (H6/H6\", m, 2H), 7.43 (H8/H8\", m, 2H), 7.66 (H7/H7\", m, 2H), 8.02 (H5/H5\", b, 2H), 11.34 (OH, s, 1H) 11.51 ppm (OH, s, 1H); ^13^C-NMR (CD~2~Cl~2~): δ 36.05 (C\*), 55.75 (OCH~3~), 104.80/106.32 (C3/C3\"), 114.32 (C3′/C5′), 117.02 (C10/C10\"), 117.13 (C8/C8\"), 124.66 (C5/C5\"), 125.40 (C6/C6\"), 127.65 (C1′), 128.19 (C2′/C6′), 133.39 (C7/C7\"), 152.89/153.01 (C9/C9\"), 159.04 (C4′), 164.88/166.20 (C4/C4\"), 167.42/169.77 ppm (C2/C2\"); ES-MS *m/z* 443 \[M−H\]. Elemental analysis. Calc. for C~26~H~18~O~7~ (%): C 70.59, H 4.10, Found: C 70.26, H 4.41.

*3,3′-(4-Methyltiobenzylidene)-bis-\[4-hydroxycoumarin\]* (**11**) \[[@B14-molecules-16-06023]\]. Yield 70%; mp 258.7 °C; IR (KBr) (ν, cm^−1^): 2916 (CH), 2114 (C--S), 1726 (C=O), 1658 (C=C--C=O), 1612, 1566, 1492, 1454 (C=C), 1400 (CH~3~), 1198 (OH); ^1^H-NMR (DMSO-d~6~): δ 2.42 (SCH~3~, s, 3H), 6.28 (H\*, s, 1H), 7.08 (H2′/H6′, m, 2H), 7.12 (H3′/H5′, m, 2H), 7.29 (H6/H6\", m, 2H), 7.33 (H8/H8\", m, 2H), 7.57 (H7/H7\", m, 2H), 7.87 ppm (H5/H5\", dd, *J* = 7.9, 1.4, 2H); ^13^C-NMR (DMSO-d~6~): δ 15.03 (SCH~3~), 35.63 (C\*), 103.80 (C3/C3\"), 115.77 (C8/C8\"), 118.57 (C10/C10\"), 123.43 (C6/C6\"), 123.94 (C5/C5\"), 126.04 (C3′/C5′), 127.40 (C2′/C6′), 131.56 (C7/C7\"), 134.30 (C4′), 137.74 (C1′), 152.29 (C9/C9\"), 164.63 (C2/C2\"), 166.06 ppm (C4/C4\"); ES-MS *m/z* 459 \[M−H\].

*3,3′-(4-Dimethylaminobenzilidene)-bis-\[4-hydroxycoumarin\]* (**12**) \[[@B11-molecules-16-06023],[@B14-molecules-16-06023]\]. Yield 65.6%; mp 205.8 °C; IR (KBr) (ν, cm^−1^): 2882 (CH), 1774 (C=O), 1665 (C=C--C=O), 1606, 1568, 1498, 1454 (C=C), 1440 (CH~3~N), 1264 (C--N), 1194 (OH); ^1^H-NMR (DMSO-d~6~): δ 3.13 (CH~3~, s, 6H), 6.28 (H\*, s, 1H), 7.24 (H6/H6\", m, 2H), 7.24 (H2′/H6′, m, 2H), 7.27 (H8/H8\", dd, *J* = 8.1, 1.1, 2H), 7.39 (H3′/H5′, m, 2H), 7.52 (H7/H7\", m, 2H), 7.81 ppm (H5/H5\", dd, *J* = 7.8, 1.4, 2H); ^13^C-NMR (DMSO-d~6~): δ 35.92 (C\*), 45.43 (CH~3~), 103.04 (C3/C3\"), 115.58 (C8/C8\"), 119.46 (C10/C10\"), 119.66 (C3′/C5′), 123.00 (C6/C6\"), 124.10 (C5/C5\"), 128.15 (C2′/C6′), 131.14 (C7/C7\"), 140.82 (C4′), 152.51 (C9/C9\"), 164.42 (C2/C2\"), 167.60 ppm (C4/C4\"); ES-MS *m/z* 456 \[M−H\]. Elemental analysis. Calc. for C~27~H~21~O~6~N: C 71.20, H 4.65, N 3.08, Found: C 71.23, H 4.61, N 3.11.

*3,3′-(3,4-Dihydroxybenzylidene)-bis-\[4-hydroxycoumarin\]* (**13**). Yield 70%; mp 227.5 °C; IR (KBr) (ν, cm^−1^): 3568 (OH), 2898 (CH), 1658 (C=O), 1604, 1566, 1498, 1452 (C=C), 1222 (OH); ^1^H-NMR (DMSO-d~6~): δ 6.20 (H\*, s, 1H), 6.39 (H6′, m, 1H), 6.55 (H2′, m, 1H), 6.58 (H5′, d, *J*=8.1, 1H), 7.33 (H6/H6\", m, 2H), 7.37 (H8/H8\", d, *J* = 7.6, 2H), 7.60 (H7/H7\", m, 2H), 7.91 ppm (H5/H5\", dd, *J* = 7.9, 1.5, 2H); ^13^C-NMR (DMSO-d~6~): δ 35.21 (C\*), 104.45 (C3/C3\"), 114.22 (C2′), 115.33 (C5′), 115.92 (C8/C8\"), 117.38 (C6′), 117.84 (C10/C10\"), 123.76 (C6/C6\"), 123.86 (C5/C5\"), 130.17 (C1′), 131.86 (C7/C7\"), 143.19 (C4′), 144.89 (C3′), 152.12 (C9/C9\"), 164.76/164.93 ppm (C2/C2\"/C4/C4\"); ES-MS *m/z* 445 \[M−H\]. Elemental analysis. Calc. for C~25~H~16~O~8~N: C 67.75, H 3.61, Found: C 67.65, H 3.66.

*3,3′-(2,5-Dimethoxybenzylidene)-bis-\[4-hydroxycoumarin\]* (**14**). Yield 72%; mp 181.6 °C; IR (KBr) (ν, cm^−1^): 2960 (CH); 1656 (C=C--C=O), 1602, 1568, 1500, 1452 (C=C), 1416 (OCH~3~), 1186 (OH); 1154 (CO); ^1^H-NMR (DMSO-d~6~): δ 3.51 (2′-OCH~3~, s, 3H), 3.62 (5′-OCH~3~, s, 3H), 6.22 (H\*, s, 1H), 6.71 (H6′, s, 1H), 6.73 (H4′, m, 1H), 6.81 (H3′, m, 1H), 7.31 (H6/H6\", m, 2H), 7.34 (H8/H8\", d, *J* = 7.3, 2H), 7.57 (H7/H7\", m, 2H), 7.90 ppm (H5/H5\", dd, *J* = 7.9, 1.5, 2H); ^13^C-NMR (DMSO-d~6~): δ 33.02 (C\*), 55.13 (2′-OCH~3~), 56.13 (5′-OCH~3~), 104.63 (C3/C3\"), 110.03 (C4′), 111.84 (C3′), 115.90 (C8/C8\"), 115.96 (C6′), 117.77 (C10/C10\"), 123.61/123.63 (C5/C5\"/C6/C6\"), 130.23 (C1′), 131.57 (C7/C7\"), 151.63 (C2′), 152.03 (C9/C9\"), 152.79 ppm (C5′), 163.96/164.03 (C2/C2\"/C4/C4\"); ES-MS *m/z* 473 \[M−H\]. Elemental analysis. Calc. for C~27~H~20~O~8~: C 68.64, H 4.27, Found: C 68.52, H 4.30.

*3,3′-(4-Hydroxy-3-methoxy-5-nitrobenzylidene)-bis-\[4-hydroxycoumarin\]* (**15**). Yield 70%; mp 199.6 °C; IR (KBr) (ν, cm^−1^): 3274 (OH), 2868 (CH), 1778 (C=O), 1658 (C=C--C=O), 1608, 1566, 1496, 1454 (C=C); 1350, 1634 (NO~2~) 1416 (OCH~3~); 1198 (OH) 1152 (CO); ^1^H-NMR (DMSO-d~6~): δ 3.67 (OCH~3~, s, 3H), 6.23 (H\*, t, *J* = 1.0, 1H), 7.01 (H2′, m, 1H), 7.18 (H6′, m, 1H), 7.29 (H6/H6\", m, 2H), 7.32 (H8/H8\", d, *J* = 7.3, 2H), 7.56 (H7/H7\", m, 2H), 7.87 ppm (H5/H5\", dd, *J* = 7.8, 1.5, 2H); ^13^C-NMR (DMSO-d~6~): δ 35.81 (C\*), 56.58 (OCH~3~), 103.35 (C3/C3\"), 113.57 (C6′), 115.80 (C8/C8\"), 115.88 (C2′), 118.73 (C10/C10\"), 123.40 (C6/C6\"), 123.99 (C5/C5\"), 131.55 (C7/C7\"), 132.16 (C1′), 136.45 (C5′), 140.89 (C4′), 149.16 (C3′), 152.37 (C9/C9\"), 164.36 (C2/C2\"), 166.45 ppm (C4/C4\"); ES-MS *m/z* 504 \[M−H\]. Elemental analysis. Calc. for C~26~H~17~O~10~N: C 62.03, H 3.40 N 2.78, Found: C 62.33, H 3.34, N 2.89.

*3-\[6-Oxo-(1H)-benzopyrano\[4,3-b\]-(1)10-hydroxybenzopyran-7-yl\]-4-hydroxycoumarin* (**16**) \[[@B17-molecules-16-06023],[@B18-molecules-16-06023]\]. Yield 82%; mp 241.7 °C; IR (KBr) (ν, cm^−1^): 2958 (CH), 1616, 1570, 1488, 1456 (C=C), 1230 (C=O); ^1^H-NMR (DMSO-d~6~): δ 5.74 (H\*, s, 1H), 7.14 (H5′, m, 1H), 7.20 (H6′, m, 1H), 7.32 (H8, m, 1H), 7.34 (H4′, m, 1H), 7.35 (H3′, m, 1H), 7.36 (H6, m, 1H), 7.46 (H8\", m, 1H), 7.49 (H6\", m, 1H), 7.60 (H7, m, 1H), 7.71 (H7\", dd, *J* = 7.5, 1.7, 1H), 8.03 (H5, m, 1H), 8.11 (H5\", dd, *J* = 7.9, 1.4, 1H), 12.21 ppm (OH, b, 1H); ^13^C-NMR (DMSO-d~6~): δ 28.64 (C\*), 100.60 (C3), 106.14 (C3\"), 113.78 (C10), 116.08/116.22/116.22 (C3′/C8\"/C10\"), 116.47 (C8), 122.20 (C1′), 122.61 (C5), 123.72 (C5\"), 123.97 (C6\"), 124.55 (C6), 125.35 (C5′), 128.36 (C4′), 128.62 (C6′), 132.19 (C7\"), 132.50 (C7), 149.16 (C2′), 151.97 (C9), 152.17 (C9\"), 156.24 (C4), 160.38 (C2), 160.66 ppm (C2\"); ES-MS *m/z* 411 \[M−H\].

*3-\[6-Oxo-(1H)-18-bromobenzopyrano\[4,3-b\]benzopyran-7-yl\]-4-hydroxycoumarin* (**17**). Yield 72%; mp 296 °C; IR (KBr) (ν, cm^−1^): 3274 (OH); 2886 (CH); 1772 (C=C--C=O), 1610, 1570, 1558, 1496, (C=C), 1220 (CO), 586 (C--Br); ^1^H-NMR (DMSO-d~6~): δ 5.71 (H\*, s, 1H), 7.31 (H6′, d, *J* = 1.8, 1H), 7.32 (H8, m, 1H), 7.34 (H3′, d, *J* = 8.7, 1H), 7.36 (H6, m, 1H), 7.45 (H8\", m, 1H), 7.49 (H6\", m, 1H), 7.52 (H4′, m, 1H), 7.61 (H7, m, 1H), 7.71 (H7\", m, 1H), 8.03 (H5, b, 1H), 8.11 (H5\", dd, *J* = 7.9, 1.4, 1H), 12.19 ppm (OH, b, 1H). ES-MS *m/z* 488 \[M−H\]. Elemental analysis. Calc. for C~25~H~13~O~6~Br: C 61.9, H 2.68, Found: C 61.7, H 2.68.

*3-\[6-Oxo-(1H)-16-methoxybenzopyrano\[4,3-b\]benzopyran-7-yl\]-4-hydroxycoumarin* (**18**). Yield 73%; mp 278.3 °C; IR (KBr) (ν, cm^−1^): 3480 (OH); 2906 (CH); 1824 (C=O); 1662 (C=C--C=O), 1620, 1586, 1496, 1460 (C=C), 1440 (OCH~3~), 1188 (OH), 990 (CO); ^1^H-NMR (DMSO-d~6~): δ 3.93 (OCH~3~, s, 3H), 5.72 (H\*, s, 1H), 6.75 (H6′, m, 1H), 7.02 (H4′, m, 1H), 7.08 (H5′, m, 1H), 7.33 (H8, m, 1H), 7.36 (H6, m, 1H), 7.45 (H8\", d, *J* = 8.2, 1H), 7.51 (H6\", m, 1H), 7.60 (H7, m, 1H), 7.70 (H7\", dd, *J* = 7.5, 1.7, 1H), 7.99 (H5\", dd, *J* = 7.8, 1.5, 1H), 8.06 (H5, m, 1H), 12.26 ppm (OH, b, 1H); ^13^C-NMR (DMSO-d~6~): δ 28.67 (C\*), 56.04 (OCH~3~), 100.38 (C3), 104.02 (C3\"), 111.18 (C4′), 113.92 (C10), 116.06 (C10\"), 116.26 (C8), 116.54 (C8\"), 119.66 (C6′), 122.38 (C5\"), 122.87 (C1′), 123.8 (C5), 123.99 (C6), 124.65 (C6\"), 125.14 (C5′), 132.23 (C7), 132.47 (C7\"), 138.64 (C2′), 147.29 (C3′), 151.93 (C9\"), 152.16 (C9), 155.94 (C4\"), 160.41/160.65 ppm (C2/C2\"/C4); ES-MS *m/z* 441 \[MH\]^+^. Elemental analysis. Calc. for C~26~H~16~O~7~: C 69.77, H 3.66, Found: C 69.85, H 3.84.

*3-\[6-Oxo-(1H)-18-nitrobenzopyrano\[4,3-b\]benzopyran-7-yl\]-4-hydroxycoumarin* (**19**). Yield 69%; mp 315.7 °C; IR (KBr) (ν, cm^−1^): 3318 (OH); 2854 (CH), 1818 (C=O); 1675 (C=C--C=O), 1610, 1586, 1498, 1456 (C=C), 1314, 1560 (NO~2~), 1190 (OH); ^1^H-NMR (DMSO-d~6~): δ 5.79 (H\*, b, 1H), 7.28 (H8, b, 1H), 7.34 (H6, b, 1H), 7.46 (H8\", d, *J* = 8.3, 1H), 7.50 (H6\", m, 1H), 7.58 (H7, b, 1H), 7.60 (H3′, d, *J* = 9.0, 1H), 7.71 (H7\", m, 1H), 8.01 (H6′, d, *J* = 2.8, 1H), 8.03 (H5, b, 1H), 8.13 (H5\", dd, *J* = 7.9, 1.6, 1H), 8.18 (H4′, dd, *J* = 9.0, 2.8, 1H), 12.49 ppm (OH, b, 1H); ES-MS *m/z* 456 \[M−H\]. Elemental analysis. Calc. for C~25~H~13~O~8~N: C 65.93, H 2.88, N 3.07, Found: C 66.02, H 2.96, N 3.04.

*3-\[6-oxo-(1H)-15,17-dimethoxybenzopyrano\[4,3-b\]benzopyran-7-yl\]-4-hydroxycoumarin* (**20**). Yield 68%; mp 287.9 °C; IR (KBr) (ν, cm^−1^): 2940 (CH), 1654 (C=C--C=O), 1596, 1570, 1494, 1456 (C=C), 1438 (OCH~3~), 1276 (CO), 1190 (OH); ^1^H-NMR (DMSO-d~6~): δ 3.67 (6′-OCH~3~, s, 3H), 3.80 (4′-OCH~3~, s, 3H), 5.57 (H\*, b, 1H), 6.36 (H5′, d, *J* = 2.4, 1H), 6.59 (H3′, d, *J* = 2.4, 1H), 7.27 (H8, d, *J* = 8.1, 1H), 7.34 (H6, m, 1H), 7.44 (H8\", m, 1H), 7.48 (H6\", m, 1H), 7.57 (H7, m, 1H), 7.69 (H7\", dd, *J* = 7.5, 1.7, 1H), 8.00 (H5, m, 1H), 8.10 (H5\", dd, *J* = 7.9, 1.4, 1H), 11.84 ppm (OH, b, 1H); ^13^C-NMR (DMSO-d~6~): δ 24.97 (C\*), 55.47 (4′-OCH~3~), 55.95 (6′-OCH~3~), 93.51 (C3′), 95.40 (C5′), 100.79 (C3), 102.59 (C1′), 104.65 (C3\"), 113.73 (C10\"), 115.97 (C8), 116.32 (C10), 116.44 (C8\"), 122.61 (C5\"), 123.79 (C5), 123.79 (C6), 124.47 (C6\"), 131.80 (C7), 132.43 (C7\"), 150.73 (C2′), 151.94 (C9\"), 152.11 (C9), 156.27 (C4\"), 157.82 (C6′), 159.71 (C4′), 160.31/160.40/160.80 ppm (C2/C2\"/C4); ES-MS *m/z* 471 \[M−H\]. Elemental analysis. Calc. for C~27~H~18~O~8~: C 68.93, H 3.86, Found: C 68.85, H 3.92.

4.3. Crystal Structure Determination of ***7***, ***9***, ***16*** and ***18*** {#sec4dot3-molecules-16-06023}
-------------------------------------------------------------------------------

Crystals suitable for X-ray single crystal structure study were grown by slow evaporation from dichloromthane for **7** and **18**, toluene for **9** and ethanol solution for **16**. The intensities were collected on an Oxford Diffraction Xcalibur2 diffractometer with a Sapphire 3 CCD detector using graphite-monochromated Mo*K~α~* radiation (*λ* = 0.71073 Å) and *ω* scan-mode at 295 K. *CrysAlisPro* \[[@B22-molecules-16-06023]\] program was used for data collection and processing. The intensities were corrected for absorption using the multi-scan absorption correction method \[[@B22-molecules-16-06023]\]. The crystal structures were solved by direct methods \[[@B23-molecules-16-06023]\] and all non-hydrogen atoms were refined anisotropically by full-matrix least-squares calculations \[[@B23-molecules-16-06023]\] based on *F*^2^ using the programs integrated in *WinGX* \[[@B24-molecules-16-06023]\] program package. The hydrogen atoms attached to the O3 and O3' atoms in **7** and **9**, O3A and O3B atoms in **16** and O3 atom in **18** were found in a difference Fourier map and are refined with O-H distance restraint of 0.82 Å. All other hydrogen atoms were treated using appropriate riding models, with *SHELXL97* defaults \[[@B23-molecules-16-06023]\]. Fluorine atoms of trifluoromethyl group in **7** are heavily disordered and restraints on anisotropic displacement parameters were therefore used in their refinement. The C29 and C31 atoms of ethanol molecules in **16** are disordered with the site occupancy factors refined to 0.62(3)/0.38(3) and 0.52(3)/0.48(3) ratio, respectively. Details of crystal data, data collection and refinement parameters are given in [Table 3](#molecules-16-06023-t003){ref-type="table"}. *PLATON* \[[@B25-molecules-16-06023]\] program was used for structure analysis and molecular and crystal structure drawings preparation. CCDC 818091-818094 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via [www.ccdc.cam.ac.uk/data_request/cif](www.ccdc.cam.ac.uk/data_request/cif).

4.4. Virological Assays {#sec4dot4-molecules-16-06023}
-----------------------

The antiviral assays, other than the anti-HIV assays, were based on inhibition of virus-induced cytopathic effect in human lung fibroblast \[herpes simplex virus type 1 (HSV-1) \[strain KOS\], herpes simplex virus type 2 (HSV-2) \[strain G\], vaccinia virus (VV) and vesicular stomatitis virus (VSV)\], African green monkey kidney (Vero, parainfluenza-3, reovirus-1, Sindbis, Coxsackie B4, and Punta Toro virus), human cervix carcinoma (vesicular stomatitis virus, Coxsackie virus B4 and respiratory syncytial virus (RSV)), feline Crandell-Rees kidney (CRFK) (feline herpes virus, feline corona virus (FIPV)) or Madin-Darby canine kidney (MDCK) (influenza A \[H1N1; H3N2\] and influenza B) cell cultures. Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID~50~ of virus (1 CCID~50~ being the virus dose to infect 50% of the cell cultures) in the presence of varying concentrations (100, 40, 8, 1.6 and 0.32 µM) of the test compounds. Viral cytopathicity was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds. The anti-HIV activity and cytotoxicity of the compounds were evaluated against wild-type HIV-1 strain III~B~ in MT-4 cell culture using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. MT-4 cells were suspended in culture medium at 1 × 10^5^ cells/mL and infected with HIV at a multiplicity of infection of 0.02. Immediately after viral infection, 100 µL of the cell suspension was placed in each well of a flat-bottomed microtiter tray containing various concentrations of the test compounds. After four days of incubation at 37 °C, the number of viable cells was determined using the MTT method. Compounds were tested in parallel for cytotoxic effects in uninfected MT-4 cells.

4. Conclusions {#sec4-molecules-16-06023}
==============

A series of the benzylidene-bis-(4-hydroxycoumarin) derivatives **1**--**15** and fused benzopyranocoumarin derivatives **16**--**20** were synthesized and evaluated for their antiviral activities on a broad panel of DNA and RNA viruses. X-ray crystal structure analysis of 4-trifluoromethylphenyl- and 2-nitrophenyl derivatives **7** and **9** revealed intramolecular hydrogen bonding between hydroxyl and carbonyl oxygen atoms of two 4-hydroxycoumarin moieties resulting in the formation of two eight-membered rings. Accordingly, two 4-hydroxycoumarin moieties in compounds **7** and **9** are anti-disposed. The 4-bromobenzylidene derivative of bis(4-hydroxycoumarin) (**3**) exerted some inhibitory activity against HSV-1 (KOS), HSV-2 (G), vaccinia virus and HSV-1 TK^-^ KOS (ACV^r^) in the range of 9--12 μM at minimum cytotoxic concentration (MCC) greater than 20 *μ*M, whereas the compounds **4**--**6**, **8**, and **20** exhibited rather pronounced anti-Feline Herpes Virus activity (EC~50~ = 5--8.1 μM) but with MCC at only 4-7-fold higher than EC~50~ values.
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*Sample Availability:* Samples of the compounds are available from the authors.

Tables S1 with hydrogen-bonded geometries, Figures S1-S4 presenting hydrogen bonds for compounds **7**, **9**, **16** and **18**.
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![(**a**) The benzylidene-bis-(4-hydroxycoumarin) derivatives **1**--**15**; (**b**) 3-\[6-oxo-(1H)-benzopyrano\[4,3-b\]benzopyran-7-yl\]-4-hydroxycoumarin derivatives **16**--**20**.](molecules-16-06023-g001){#molecules-16-06023-f001}

![Synthesis of coumarin-dimer derivatives with variously substituted aryl central linkers (**1**--**15**) and fused benzopyranocoumarin derivatives **16**--**20**. Reagents and conditions: (*i*) EtOH, heating under reflux for 24 h.](molecules-16-06023-sch001){#molecules-16-06023-sch001}

![Key NOE enhancements in **5** (**a**) and **14** (**b**). Dotted lines present hydrogen bonds.](molecules-16-06023-g002){#molecules-16-06023-f002}

![^1^H-NMR spectra of **20** dissolved in DMSO-d6 at temperatures in the range from 298 to 358 K.](molecules-16-06023-g003){#molecules-16-06023-f003}

![A view of **7** (**a**) and **9** (**b**), with the atom-numbering scheme. Displacement ellipsoids for non-hydrogen atoms are drawn at the 20% and 30% probability level for **7** and **9**, respectively. Intramolecular hydrogen bonds are indicated by dashed lines.](molecules-16-06023-g004){#molecules-16-06023-f004}

![A view of **16** (**a**) and **18** (**b**), with the atom-numbering scheme. For clarity, only one independent molecule of **16** is shown. Displacement ellipsoids for non-hydrogen atoms are drawn at the 30% probability level. Intramolecular hydrogen bond in 18 is indicated by dashed line.](molecules-16-06023-g005){#molecules-16-06023-f005}

molecules-16-06023-t001_Table 1

###### 

Cytotoxicity and antiviral activity of coumarin derivatives **3**, **7**, **8**, **11**, **13**--**15**, **19** and **20** in HEL cell cultures.

  Compound      MCC ^a^ (μM)   EC~50~ ^b^ (μM)                           
  ------------- -------------- ----------------- ------- ------- ------- -------
  **3**         \>20           9                 9       11      \>20    9
  **7**         20             \>4               \>4     \>4     \>4     \>4
  **8**         100            \>20              \>20    \>20    \>20    \>20
  **11**        100            \>20              \>20    \>20    \>20    \>20
  **13**        100            \>20              \>20    \>20    \>20    \>20
  **14**        \>100          \>100             \>100   \>100   \>100   \>100
  **15**        \>100          \>100             \>100   \>100   \>100   \>100
  **19**        \>100          50                45      \>100   \>100   50
  **20**        100            \>20              \>20    \>20    \>20    \>20
  Brivudin      \>250          0.06              182     3.2     \>250   50
  Cidofovir     \>250          0.9               1.5     7.9     \>250   1.5
  Acyclovir     \>250          0.30              0.35    \>250   \>250   20
  Ganciclovir   \>100          0.025             0.030   \>100   \>100   0.1

^a^ Minimum cytotoxic concentration, as determined by examining the microscopically visible morphological alteration of the cell cultures; ^b^ 50% Effective concentration, or concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay.

molecules-16-06023-t002_Table 2

###### 

Cytotoxicity in CRFK cell cultures and anti-Feline Corona Virus (FIPV) and anti-Feline Herpes Virus activity of coumarin derivatives **1**, **4**--**6**, **8**, **9** and **20**.

  Compound      Minimum cytotoxic conc. in CRFK cell cultures (CC~50~) ^a^ (μM)   EC~50~ ^b^ (μM)   
  ------------- ----------------------------------------------------------------- ----------------- ------
  **1**         43                                                                7.5               9.1
  **4**         45                                                                9.1               7.6
  **5**         36                                                                7.5               5.0
  **6**         39                                                                7.7               8.1
  **8**         41                                                                8.5               6.9
  **9**         34                                                                8.3               14
  **20**        27                                                                6.4               7.1
  HHA           \> 2                                                              0.34              0.15
  UDA           \>10                                                              4.2               7.1
  Ganciclovir   \>100                                                             \>100             4.9

^a^ 50% Cytotoxic concentration, as determined by measuring the cell viability by the colorimetric formazan-based MTS assay; ^b^ 50% Effective concentration, or compound concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay.

molecules-16-06023-t003_Table 3

###### 

X-ray crystallographic data for compounds **7**, **9**, **16** and **18**.

  Compound                                       7                    9                    16                   18
  ---------------------------------------------- -------------------- -------------------- -------------------- --------------------
  Formula                                        C~26~H~15~F~3~O~6~   C~25~H~15~NO~8~      C~54~H~42~O~15~      C~26~H~16~O~7~
  Formula weight                                 480.38               457.38               930.88               440.39
  Crystal size \[mm\]                            0.44 × 0.24 × 0.22   0.28 × 0.24 × 0.20   0.62 × 0.35 × 0.29   0.48 × 0.14 × 0.09
  Crystal colour, shape                          colourless, block    colourless, block    colourless, prism    colourless, prism
  Crystal system                                 monoclinic           monoclinic           monoclinic           triclinic
  Space group                                    *P* 2~1~/*c*         *C* 2/*c*            *P* 2~1~/*c*         *P* $\overline{1}$
  Unit cell dimensions                                                                                          
  *a* \[Å\]                                      10.4430(4)           34.4429(19)          18.6160(10)          9.4927(4)
  *b* \[Å\]                                      10.4031(4)           7.5448(3)            15.2918(5)           9.7660(4)
  *c* \[Å\]                                      20.1801(9)           16.8941(9)           17.7112(10)          11.8741(5)
  *α* \[°\]                                      90                   90                   90                   66.322(4)
  *β* \[°\]                                      91.423(3)            112.749(6)           115.484(7)           73.399(4)
  *γ* \[°\]                                      90                   90                   90                   83.084(3)
  *V* \[Å^3^\]                                   2191.68(15)          4048.7(3)            4551.3(4)            966.09(7)
  *Z*                                            4                    8                    4                    2
  *D*~calc.~ \[g cm^−3^\]                        1.456                1.501                1.359                1.514
  *μ* \[mm^−1^\]                                 0.120                0.114                0.100                0.111
  *θ* range \[°\]                                4.14 to 26.00        4.19 to 26.00        4.16 to 26.00        4.21 to 26.00
  Collected reflections No.                      17378                21957                41605                13789
  Independent reflections No. / *R*~int.~        4298 / 0.0279        3970 / 0.0229        8906 / 0.0477        3777 / 0.0315
  Reflections number *I* ≥ 2σ(*I*)               2649                 2694                 5836                 2341
  Data / restraints / parameters                 4298 / 20 / 324      3970 / 2 / 315       8906 / 6 / 666       3777 / 1 / 303
  Goodness-of-fit on *F*^2^                      0.999                1.010                1.020                0.997
  *R* \[*I* ≥ 2*σ*(*I*)\] / *R* \[all data\]     0.0611 / 0.0926      0.0391 / 0.0587      0.0453 / 0.0878      0.0390 / 0.0707
  *wR* \[*I* ≥ 2*σ*(*I*)\] / *wR* \[all data\]   0.2004 / 0.2150      0.1103 / 0.1158      0.1039 / 0.1305      0.0954 / 0.1043
  Max./min. elect. density \[e Å^−3^\]           0.543 / −0.425       0.388/ −0.186        0.189 / −0.270       0.216 / −0.174
